Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Working Capital Changes (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Other Working Capital Changes for 5 consecutive years, with -$168000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 91.71% year-over-year to -$168000.0, compared with a TTM value of -$151000.0 through Dec 2025, up 94.37%, and an annual FY2025 reading of -$151000.0, up 94.37% over the prior year.
  • Other Working Capital Changes was -$168000.0 for Q4 2025 at Aligos Therapeutics, down from $207000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $10.2 million in Q3 2022 and bottomed at -$3.6 million in Q1 2022.
  • Average Other Working Capital Changes over 5 years is -$356000.0, with a median of -$445000.0 recorded in 2021.
  • Peak annual rise in Other Working Capital Changes hit 948.67% in 2022, while the deepest fall reached 1094.72% in 2022.
  • Year by year, Other Working Capital Changes stood at -$3.4 million in 2021, then soared by 36.63% to -$2.1 million in 2022, then skyrocketed by 148.64% to $1.0 million in 2023, then plummeted by 294.9% to -$2.0 million in 2024, then skyrocketed by 91.71% to -$168000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for ALGS at -$168000.0 in Q4 2025, $207000.0 in Q3 2025, and -$39000.0 in Q2 2025.